Page last updated: 2024-10-21

phenytoin and Anoxia, Brain

phenytoin has been researched along with Anoxia, Brain in 24 studies

Research Excerpts

ExcerptRelevanceReference
" This report describes a near-hanging episode in a patient who subsequently had status epilepticus requiring 40 mg of diazepam and 1,200 mg of phenytoin for control in the prehospital and emergency department stabilization period."3.70Hanging-induced status epilepticus. ( Pesola, GR; Westfal, RE, 1999)
"A 75-year-old man suffered a cardiac arrest and severe anoxic encephalopathy."1.30Periodic complexes, absence-like status and suppression-burst pattern in coma following cardiorespiratory arrest. ( Chemmale, J; Devrajan, VN; Ganji, SS; McDonald, L; Palliyath, S, 1997)
"In complete global ischemia (cardiac arrest) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state."1.29[Cerebral protection]. ( Cattaneo, AD, 1993)
"When phenytoin was administered immediately after the hypoxia, there was no difference between vehicle-injected controls and phenytoin-treated pups."1.29Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. ( Hamada, Y; Hattori, H; Hayakawa, T; Maihara, T; Mikawa, H, 1994)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-199014 (58.33)18.7374
1990's9 (37.50)18.2507
2000's1 (4.17)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hosseinzadeh, H1
Sadati, N1
CELESIA, GG1
ANDERMANN, F1
HUGHES, JR1
SCHLAGENHAUFF, RE1
Shiu, GK1
Nemoto, EM1
Nemmer, J1
Koller, WC1
Glatt, SL1
Perlik, S1
Huckman, MS1
Fox, JH1
Wohns, RN1
Kerstein, MD1
Artru, AA1
Michenfelder, JD1
Lampley, EC1
Mishra, OP1
Graham, E1
Delivoria-Papadopoulos, M1
Weber, ML1
Taylor, CP2
Domenici, MR1
Sagratella, S1
Frank, C1
Scotti de Carolis, A1
Cattaneo, AD1
Hayakawa, T1
Hamada, Y1
Maihara, T1
Hattori, H1
Mikawa, H1
Vartanian, MG1
Cordon, JJ1
Kupina, NC1
Schielke, GP1
Posner, A1
Raser, KJ1
Wang, KK1
Ganji, SS1
Palliyath, S1
Chemmale, J1
Devrajan, VN1
McDonald, L1
Toner, CC1
Stamford, JA1
Pesola, GR1
Westfal, RE1
Aldrete, JA1
Romo-Salas, F1
Jankovsky, L1
Franatovic, Y1
Moss, G4
Stein, AA3
Goto, K1
Suekawa, M1
Aburada, M1
Hosoya, E1
Heuser, D1
Guggenberger, H1
Staunton, C1
Gordon, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Reviews

2 reviews available for phenytoin and Anoxia, Brain

ArticleYear
Ionic changes in brain ischaemia and alterations produced by drugs.
    British journal of anaesthesia, 1985, Volume: 57, Issue:1

    Topics: Animals; Biological Transport, Active; Brain Ischemia; Calcium; Calcium Channel Blockers; Cats; Extr

1985
Molecular approaches to the drug enhancement of deteriorated functioning in the aged.
    Advances in gerontological research, 1971, Volume: 3

    Topics: 1-Propanol; Aging; Amino Alcohols; Amphetamine; Animals; Brain; Cognition; Deoxyribonucleases; DNA;

1971

Other Studies

22 other studies available for phenytoin and Anoxia, Brain

ArticleYear
The protective effect of Allium sativum L. clove aqueous and methanolic extracts against hypoxia-induced lethality in mice.
    Phytotherapy research : PTR, 2003, Volume: 17, Issue:3

    Topics: Animals; Dose-Response Relationship, Drug; Female; Garlic; Hypoxia, Brain; Injections, Intraperitone

2003
SOME OBSERVATIONS ON THE ELECTROGRAPHIC CORRELATES OF THE DECEREBRATE ATTACK.
    Electroencephalography and clinical neurophysiology, 1964, Volume: 16

    Topics: Child; Coma; Decerebrate State; Electroencephalography; Epilepsy; Humans; Hypoxia, Brain; Infusions,

1964
THE PERIODICALLY RECURRING FOCAL DISCHARGE.
    Epilepsia, 1965, Volume: 6

    Topics: Animals; Cerebrovascular Disorders; Child; Drug Therapy; Electrocardiography; Electroencephalography

1965
Dose of thiopental, pentobarbital, and phenytoin for maximal therapeutic effects in cerebral ischemic anoxia.
    Critical care medicine, 1983, Volume: 11, Issue:6

    Topics: Animals; Brain Chemistry; Brain Ischemia; Fatty Acids, Nonesterified; Female; Hypoxia, Brain; Ketami

1983
Cerebellar atrophy demonstrated by computed tomography.
    Neurology, 1981, Volume: 31, Issue:4

    Topics: Adult; Alcoholism; Atrophy; Carcinoma; Cerebellar Diseases; Cerebellar Neoplasms; Cerebral Ventricul

1981
The role of dilantin in the prevention of pulmonary edema associated with cerebral hypoxia.
    Critical care medicine, 1982, Volume: 10, Issue:7

    Topics: Animals; Brain; Disease Models, Animal; Dogs; Female; Hemorrhage; Hypoxia, Brain; Lung; Male; Perfus

1982
Anoxic cerebral potassium accumulation reduced by phenytoin: mechanism of cerebral protection?
    Anesthesia and analgesia, 1981, Volume: 60, Issue:1

    Topics: Animals; Cisterna Magna; Dose-Response Relationship, Drug; Heart Arrest; Hypothermia, Induced; Hypox

1981
Neuroprotective effect of phenytoin against in utero hypoxic brain injury in fetal guinea pigs.
    Neuroscience letters, 1995, Feb-17, Volume: 186, Issue:2-3

    Topics: Animals; Cell Membrane; Chromatography, High Pressure Liquid; Female; Fetal Hypoxia; Guinea Pigs; Hy

1995
Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials.
    Brain research, 1994, Nov-21, Volume: 664, Issue:1-2

    Topics: Action Potentials; Animals; Brain Ischemia; Evoked Potentials; Hippocampus; Hypoxia, Brain; In Vitro

1994
Effects of non-opioid antitussives on hypoxia-induced electrical changes in rat hippocampal slices: a comparative study with anticonvulsant drugs.
    General pharmacology, 1993, Volume: 24, Issue:4

    Topics: Animals; Anticonvulsants; Antitussive Agents; Cyclopentanes; Dizocilpine Maleate; Electrophysiology;

1993
[Cerebral protection].
    Minerva anestesiologica, 1993, Volume: 59, Issue:9

    Topics: Adrenal Cortex Hormones; Anesthetics; Barbiturates; Benzodiazepines; Brain Ischemia; Calcium Channel

1993
Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats.
    Life sciences, 1994, Volume: 54, Issue:6

    Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Corpus Stria

1994
Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats.
    Brain research. Developmental brain research, 1996, Sep-02, Volume: 95, Issue:2

    Topics: Animals; Animals, Newborn; Anticonvulsants; Body Temperature Regulation; Brain Damage, Chronic; Brai

1996
Periodic complexes, absence-like status and suppression-burst pattern in coma following cardiorespiratory arrest.
    Clinical EEG (electroencephalography), 1997, Volume: 28, Issue:2

    Topics: Aged; Anticonvulsants; Brain; Coma; Diazepam; Electroencephalography; Epilepsy, Absence; Heart Arres

1997
Sodium channel blockade unmasks two temporally distinct mechanisms of striatal dopamine release during hypoxia/hypoglycaemia in vitro.
    Neuroscience, 1997, Volume: 81, Issue:4

    Topics: Animals; Dopamine; Electrophysiology; Extracellular Space; Hypoglycemia; Hypoxia, Brain; In Vitro Te

1997
Hanging-induced status epilepticus.
    The American journal of emergency medicine, 1999, Volume: 17, Issue:1

    Topics: Adult; Anticonvulsants; Diazepam; Drug Therapy, Combination; Electroencephalography; Emergency Treat

1999
Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits.
    Critical care medicine, 1979, Volume: 7, Issue:10

    Topics: Animals; Brain Ischemia; Hypoxia, Brain; Phenytoin; Placebos; Rabbits; Thiopental

1979
Cerebral etiology of the acute respiratory distress syndrome: diphenylhydantoin prophylaxis.
    The Journal of trauma, 1975, Volume: 15, Issue:1

    Topics: Animals; Bronchial Diseases; Disease Models, Animal; Dogs; Female; Hypoxia, Brain; Lung; Male; Pheny

1975
[Pharmacological study of TJ-8007 (Tsumura-Zokumeito) (I): Protective effects of TJ-8007 against anoxic brain damage].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1987, Volume: 89, Issue:6

    Topics: Animals; Brain Damage, Chronic; Coma; Drugs, Chinese Herbal; Hypoxia, Brain; Male; Medicine, Chinese

1987
Shock, cerebral hypoxia, and pulmonary vascular control: the centrineurogenic etiology of the respiratory distress syndrome.
    Bulletin of the New York Academy of Medicine, 1973, Volume: 49, Issue:8

    Topics: Animals; Animals, Newborn; Brain; Cattle; Cerebrovascular Circulation; Denervation; Dogs; Goats; Hap

1973
Cerebral etiology of the respiratory distress syndrome: universal response, with prevention by unilateral pulmonary denervation.
    Surgical forum, 1973, Volume: 24

    Topics: Animals; Cattle; Denervation; Dogs; Goats; Haplorhini; Humans; Hypoxia, Brain; Infant, Newborn; Lung

1973
Cerebral etiology of the respiratory distress syndrome: diphenylhydantoin (DPH) prophylaxis.
    Surgical forum, 1973, Volume: 24

    Topics: Anemia; Animals; Bloodletting; Cardiac Output; Denervation; Dogs; Female; Hypoxia, Brain; Lactates;

1973